Immunotherapy against neuroserpin to correct Nerve Growth Factor metabolic dysfunction and consequent cholinergic and cognitive deficits in a transgenic rat model of Alzheimer's disease.

针对神经丝氨酸蛋白酶抑制剂的免疫疗法可纠正阿尔茨海默病转基因大鼠模型中的神经生长因子代谢功能障碍以及随之而来的胆碱能和认知缺陷。

• 批准号: 365444
• 负责人: Pentz Rowan D
• 金额: $ 7.65万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-10-01 至 2019-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=365444&lang=en
• 关键词: Alzhiemer'S Disease; Basal Forebrain; Behavioural Testing; Cholinergic System; Immunotherapy; Inflammation; Nerve Growth Factor; Neurodegeneration; Ngf Metabolic Pathway; Transgenic Models

Alzheimer's disease (AD) is an increasing problem in our aging population. Unless new disease-modifying treatments are discovered, the problem may become unmanageable. In AD, cholinergic neurons of the basal forebrain become atrophic or die, and most brai

阿尔茨海默病（AD）是我们老龄化人口中日益严重的问题。除非发现新的改善疾病的治疗方法，否则这个问题可能会变得无法控制。 在AD中，基底前脑的胆碱能神经元萎缩或死亡，大多数脑组织中的胆碱能神经元在AD发病后出现萎缩或死亡。